Stock listing

OTC:ATXI Avenue Therapeutics, Inc. Stock

Home listing (OTC) of Avenue Therapeutics, Inc.

Follow Avenue Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · OTC:ATXI

$0.28 USD 0.00 (0.0%)

Close on Nov 16, 2026

Past year -65.0% · daily closes, Nov 17, 2025 – Nov 16, 2026, adjusted for splits
Day range
$0.28 – $0.28 USDNov 16, 2026
Volume
7 sharesNov 16, 2026
Market cap
$922,591 USDAt the close on Nov 16, 2026 · price × 3.29M shares outstanding
52-week range
$0.15 – $0.957 USDLowest and highest trades, Nov 17, 2025 – Nov 16, 2026
Traded on an average day
$2,931 USDMedian day 329 shares · 21 days with no trades · last 3 months, Aug 17, 2026 – Nov 16, 2026
Avenue Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
OTC:ATXI · Home$0.28 USD0.00 (0.0%)7$0.28$0.28$0.28$0.28Close on Nov 16, 2026

Daily closes

Last 3 months, Aug 17, 2026 – Nov 16, 2026 · OTC:ATXI · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.280.000.0%$0.28$0.28$0.287
$0.280.000.0%$0.28$0.28$0.280
$0.28-0.025-8.3%$0.28$0.28$0.282,828
$0.3050.000.0%$0.305$0.305$0.3050
$0.3050.000.0%$0.305$0.305$0.3050
$0.305-0.124-28.8%$0.28$0.429$0.281,129
$0.4290.000.0%$0.429$0.429$0.4290
$0.429+0.027+6.7%$0.429$0.429$0.429117
$0.4020.000.0%$0.402$0.402$0.4020
$0.4020.000.0%$0.402$0.402$0.4020
$0.402-0.026-6.1%$0.402$0.402$0.4022,097
$0.428+0.048+12.6%$0.428$0.428$0.428301
$0.380.000.0%$0.38$0.38$0.380
$0.38-0.019-4.6%$0.38$0.38$0.385,007
$0.399-0.014-3.3%$0.417$0.417$0.3992,115
$0.412+0.027+7.1%$0.402$0.412$0.4010,999
$0.385-0.019-4.8%$0.385$0.385$0.385234
$0.4040.000.0%$0.404$0.404$0.4040
$0.4040.000.0%$0.404$0.404$0.4040
$0.404-0.026-6.0%$0.404$0.404$0.404104
$0.430.000.0%$0.43$0.43$0.430
$0.430.000.0%$0.43$0.43$0.430
$0.430.000.0%$0.43$0.43$0.430
$0.43+0.01+2.4%$0.43$0.43$0.43329
$0.42+0.019+4.9%$0.44$0.44$0.423,036
$0.401-0.029-6.8%$0.449$0.449$0.401488
$0.430.000.0%$0.43$0.43$0.430
$0.43-0.019-4.3%$0.43$0.43$0.43249
$0.449+0.069+18.2%$0.382$0.449$0.3826,121
$0.380.000.0%$0.38$0.38$0.380
$0.38-0.028-6.8%$0.38$0.38$0.38604
$0.408+0.048+13.2%$0.408$0.408$0.4081,082
$0.36-0.04-10.0%$0.40$0.492$0.3619,791
$0.400.000.0%$0.27$0.40$0.2710,241
$0.40-0.10-20.0%$0.465$0.465$0.4015,165
$0.500.000.0%$0.50$0.50$0.500
$0.500.000.0%$0.50$0.50$0.500
$0.50+0.14+38.9%$0.40$0.68$0.409,236
$0.36-0.14-28.0%$0.26$0.36$0.26395
$0.50+0.022+4.7%$0.46$0.538$0.254,912
$0.4780.000.0%$0.478$0.478$0.4780
$0.4780.000.0%$0.478$0.478$0.4780
$0.478-0.086-15.3%$0.546$0.546$0.4510,715
$0.564-0.071-11.2%$0.66$0.66$0.5643,515
$0.635-0.047-6.8%$0.642$0.72$0.62540,983
$0.682+0.082+13.6%$0.60$0.682$0.5421,465
$0.60-0.224-27.2%$0.80$0.90$0.6030,817
$0.824+0.172+26.4%$0.652$0.846$0.65237,513
$0.652+0.112+20.7%$0.57$0.652$0.5647,408
$0.54-0.004-0.8%$0.55$0.55$0.5025,756
$0.545-0.025-4.5%$0.52$0.57$0.4884,000
$0.570.000.0%$0.57$0.57$0.570
$0.57+0.05+9.6%$0.52$0.57$0.44510,256
$0.52+0.068+15.0%$0.577$0.577$0.5193,020
$0.4520.000.0%$0.452$0.452$0.452308
$0.452-0.125-21.7%$0.49$0.49$0.4525,140
$0.577+0.127+28.2%$0.47$0.577$0.43223,056
$0.45+0.04+9.8%$0.40$0.45$0.4030,095
$0.41+0.152+59.2%$0.40$0.419$0.4017,816
$0.2580.000.0%$0.258$0.258$0.2580
$0.2580.000.0%$0.258$0.258$0.2581
$0.2580.000.0%$0.258$0.258$0.2580
$0.2580.000.0%$0.258$0.258$0.2583
$0.2580.000.0%$0.258$0.258$0.25836
$0.2580.000.0%$0.258$0.258$0.25893

Splits

2 splits since 2022 · OTC:ATXI · every price before a split is adjusted for it

DayRatioWhat
1-for-75Consolidation
1-for-15Consolidation
Ticker
OTC:ATXI
Asset type
Stock
Exchange
OTC
Currency
USD

What changed lately

Latest news

All Avenue Therapeutics, Inc. news

Avenue Therapeutics, Inc. on 6ix

News releases
1 in the last 12 months · 2 in all · newest Feb 23, 2026 · oldest 2025
Decks
17 decks · latest Oct 4, 2023

Where Avenue Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
OTC:ATXI · Home listing · This pageOTCUnited StatesUSD
Lang & Schwarz:A40BWJLang & SchwarzGermanyEUR
LS Exchange:A40BWJLS ExchangeGermanyEUR

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 16, 2026

Enterprise value
−$597,409 USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
-1.55

Team and board

Officers

OfficerRole
Alexandra MacLeanChief Executive Officer, Director
David JinInterim Chief Financial Officer and Chief Operating Officer

Board

DirectorRole
Jay KranzlerChairman of the Board of Directors
Alexandra MacLeanChief Executive Officer, Director
Curtis OltmansDirector
Faith CharlesDirector
Lindsay A. RosenwaldDirector
Neil HerskowitzDirector

Events

QuarterResultsShare move
Q3 2025Nov 13, 2025+1.2%
Q2 2025Aug 14, 2025+14.0%
Q1 2025May 13, 2025 · Before open−25.4%
Q4 2024Mar 31, 2025−6.8%
Q3 2024Nov 14, 2024 · After close+2.7%
Q2 2024Aug 9, 2024 · After close+0.6%
Q1 2024May 15, 2024 · After close−0.6%
Q4 2023Mar 18, 2024 · After close0.0%
Q3 2023Nov 13, 2023 · After close+1.0%
Q2 2023Aug 10, 2023 · After close−0.9%
All 20 quarters
QuarterResultsShare move
Q1 2023May 12, 2023 · Before open+3.4%
Q4 2022Mar 30, 2023 · After close+5.9%
Q3 2022Nov 10, 2022 · After close−10.4%
Q2 2022Aug 15, 2022 · Before open+1.1%
Q1 2022May 16, 2022 · Before open−1.8%
Q4 2021Mar 25, 2022 · After close−21.1%
Quarter to Sep 30, 2021Nov 15, 2021 · Before open−0.7%
Quarter to Jun 30, 2021Aug 16, 2021 · After close−3.7%
Quarter to Mar 31, 2021May 17, 2021 · Before open+0.2%
Quarter to Dec 31, 2020Mar 31, 2021 · Before open+5.6%

Open Events

Decks

DeckKindSlidesDate
IPO Roadshow (October 2023)IPO roadshow27 slidesOct 4, 2023
Investor Presentation (August 2023)Investor deck24 slidesAugust 2023
Investor Presentation (June 2023)Investor deck21 slidesJune 2023
Investor Presentation (March 2023)Investor deck35 slidesMarch 2023
Investor Presentation (January 2023)Investor deck24 slidesJanuary 2023
Investor Presentation (November 2022)Investor deck24 slidesNovember 2022
IPO Roadshow (October 2022)IPO roadshow30 slidesOct 6, 2022
Investor Presentation (May 2018)Investor deck24 slidesMay 25, 2018
Investor Presentation (July 2017)Investor deck20 slidesJul 14, 2017
Investor Presentation (May 2017)Investor deck15 slidesMay 2017
All 17 decks
DeckKindSlidesDate
Investor Presentation (March 2017)Investor deck16 slidesMarch 2017
Investor Presentation (February 2017)Investor deck16 slidesFebruary 2017
Investor Presentation (February 2017)Investor deck16 slidesFebruary 2017
Investor Presentation (January 2017)Investor deck16 slidesJanuary 2017
Investor Presentation (December 2016)Investor deck15 slidesDecember 2016
Investor Presentation (September 2016)Investor deck14 slidesSeptember 2016
Investor Presentation (August 2016)Investor deck12 slidesAugust 2016

Open Decks

IPO

Priced at US$6.00 a share on Jun 26, 2017.

Price
US$6.00 a share
Shares offered
5,500,000 shares of common stock
Offering size
US$33 million
Underwriters
OPPENHEIMER & CO., NATIONAL SECURITIES CORPORATION · In the order on the cover
Shares delivered
On or about Jun 30, 2017

Steps

StepWhen
Draft sent to the SEC in confidenceMar 28, 2017
Filed publiclyApr 28, 2017
Amended 3 timesNewest Jun 23, 2017
Shares registered with an exchangeJun 14, 2017
Declared effective by the SECJun 26, 2017
Final prospectus, with the priceJun 28, 2017

Open IPO · From the cover of the final prospectus (424B2) filed Jun 28, 2017

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.40M0
Research and development1.04M6.64M6.13M2.70M1.25M2.87M22.2M17.7M6.70M1.33M
Operating income-3.08M-11.3M-14.5M-8.04M-3.74M-5.21M-26.3M-21.8M-11.4M-2.38M
Interest expense0294.0K420.0K
Income tax2.00K000
Net income-2.91M-11.7M-10.4M-3.55M-3.73M-5.15M-25.9M-21.5M-12.3M-3.18M
Earnings per share, basic-0.93-15.79-73.48-1.63-0.22-0.31-1.65-2.10-1.85-1.11
Earnings per share, diluted-0.22-0.31-1.65-2.10-1.85-1.11

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents2.85M2.59M1.78M6.71M3.76M3.13M8.74M2.67M11.8M197.0K
Short-term investments010.0M0
Current assets3.96M3.25M
Total assets2.93M2.67M1.85M6.84M3.96M3.25M8.91M4.53M22.2M197.0K
Accounts payable155.0K78.0K129.0K304.0K143.0K354.0K3.09M1.54M334.0K
Current liabilities1.10M816.0K1.20M3.58M509.0K886.0K2.12M5.16M2.79M6.42M
Total liabilities1.10M816.0K1.20M3.58M509.0K886.0K2.12M5.16M2.79M8.45M
Shareholders' equity1.83M2.80M1.58M3.90M3.45M2.36M6.80M-631.0K19.4M-8.25M
Shares outstanding3.18M2.11M341.3K4.77M1.41M16.7M16.7M10.7M10.3M3.26M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-1.83M-9.03M-9.45M-7.60M-3.75M-4.61M-26.3M-18.2M-6.80M-1.63M
Cash from investing0-3.00M0-1.00M010.0M-10.0M0
Cash from financing2.09M9.84M7.53M10.5M4.38M032.3M-895.0K28.4M1.81M
Share buybacks0-1.10M
Change in cash261.0K811.0K-4.92M2.94M631.0K-5.61M6.07M-9.11M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 6, 2026Quarterly reportSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
10-Q · Quarterly reportMay 8, 2026Quarterly reportSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
8-K · Current reportFeb 23, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 6, 2026Big-stake noticeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
8-K · Current reportDec 31, 2025Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveDec 17, 2025Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
POS AM · Amendment to an effective registrationDec 15, 2025Offer documentSEC
RW · Request to withdraw a registrationDec 15, 2025Other filingsSEC
DEF 14A · Proxy statementDec 5, 2025Meeting noticeSEC
8-K · Current reportNov 18, 2025Current reportSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025Material contractSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
25-NSEJul 18, 2025Other filingsSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportApr 30, 2025Acquisition or disposalSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 2, 2025Big-stake noticeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
8-K · Current reportMar 17, 2025Current reportSEC
8-K · Current reportMar 7, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 3, 2025Big-stake noticeSEC
3 · Initial statement of ownershipJan 3, 2025Insider tradeSEC
S-3 · Registration statementDec 4, 2024Offer documentSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
8-K · Current reportNov 29, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedNov 15, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
4 · Change in ownershipNov 7, 2024Insider tradeSEC
4 · Change in ownershipOct 1, 2024Insider tradeSEC
8-K · Current reportSep 27, 2024Management or board changeSEC
4 · Change in ownershipSep 25, 2024Insider tradeSEC
4 · Change in ownershipSep 25, 2024Insider tradeSEC
4 · Change in ownershipSep 25, 2024Insider tradeSEC
4 · Change in ownershipSep 25, 2024Insider tradeSEC
4 · Change in ownershipSep 25, 2024Insider tradeSEC
4 · Change in ownershipSep 25, 2024Insider tradeSEC
4 · Change in ownershipSep 25, 2024Insider tradeSEC
10-Q · Quarterly reportAug 9, 2024Quarterly reportSEC
8-K · Current reportAug 9, 2024ResultsSEC
S-8 · Registration statement for employee plansJul 12, 2024Offer documentSEC
8-K · Current reportJun 26, 2024Management or board changeSEC
8-K · Current reportMay 23, 2024Current reportSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
8-K · Current reportMay 15, 2024ResultsSEC
EFFECT · Notice that a registration is effectiveMay 13, 2024Other filingsSEC
8-K · Current reportMay 10, 2024Material contractSEC
424B3 · ProspectusMay 10, 2024Offer documentSEC
424B5 · ProspectusMay 10, 2024Offer documentSEC
CORRESP · Letter to the SECMay 8, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 8, 2024Other filingsSEC
S-3 · Registration statementMay 3, 2024Offer documentSEC
DEFA14A · Additional proxy materialMay 3, 2024Meeting noticeSEC
DEF 14A · Proxy statementMay 3, 2024Meeting noticeSEC
SC 13G/A · Big-stake notice, amendedMay 2, 2024Big-stake noticeSEC
8-K · Current reportMay 1, 2024Material contractSEC
8-K · Current reportApr 26, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedApr 17, 2024Big-stake noticeSEC
4 · Change in ownershipApr 17, 2024Insider tradeSEC
8-K · Current reportMar 29, 2024Current reportSEC
DEF 14CMar 18, 2024Meeting noticeSEC
10-K · Annual reportMar 18, 2024Annual reportSEC
8-K · Current reportMar 18, 2024ResultsSEC
8-K · Current reportMar 15, 2024Current reportSEC
PRE 14CMar 8, 2024Meeting noticeSEC
8-K · Current reportMar 8, 2024Meeting outcomeSEC
8-K · Current reportFeb 23, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveFeb 2, 2024Other filingsSEC
424B3 · ProspectusFeb 1, 2024Offer documentSEC
CORRESP · Letter to the SECJan 30, 2024Other filingsSEC
UPLOAD · Letter from the SECJan 29, 2024Other filingsSEC
DEF 14CJan 29, 2024Meeting noticeSEC
S-3 · Registration statementJan 24, 2024Offer documentSEC
PRE 14CJan 17, 2024Meeting noticeSEC
8-K · Current reportJan 12, 2024Meeting outcomeSEC
8-K · Current reportJan 8, 2024Material contractSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJan 2, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedDec 13, 2023Big-stake noticeSEC
4 · Change in ownershipDec 13, 2023Insider tradeSEC
SC 13G · Big-stake noticeNov 28, 2023Big-stake noticeSEC
3 · Initial statement of ownershipNov 28, 2023Insider tradeSEC
8-K · Current reportNov 24, 2023Current reportSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
8-K · Current reportNov 13, 2023ResultsSEC
8-K · Current reportNov 2, 2023Material contractSEC
424B4 · ProspectusNov 2, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 1, 2023Other filingsSEC
CORRESP · Letter to the SECOct 30, 2023Other filingsSEC
CORRESP · Letter to the SECOct 30, 2023Other filingsSEC
CORRESP · Letter to the SECOct 27, 2023Other filingsSEC
CORRESP · Letter to the SECOct 27, 2023Other filingsSEC
CORRESP · Letter to the SECOct 24, 2023Other filingsSEC
CORRESP · Letter to the SECOct 24, 2023Other filingsSEC
S-1/A · Registration statement, amendedOct 23, 2023Offer documentSEC
FWP · Free writing prospectusOct 5, 2023Offer documentSEC
FWP · Free writing prospectusOct 3, 2023Offer documentSEC
S-1/A · Registration statement, amendedSep 29, 2023Offer documentSEC
8-K · Current reportSep 28, 2023Current reportSEC
8-K · Current reportSep 27, 2023Current reportSEC
UPLOAD · Letter from the SECSep 21, 2023Other filingsSEC
S-1 · Registration statementSep 18, 2023Offer documentSEC
SC 13D/A · Big-stake notice, amendedSep 18, 2023Big-stake noticeSEC
4 · Change in ownershipSep 12, 2023Insider tradeSEC
4 · Change in ownershipSep 12, 2023Insider tradeSEC
8-K · Current reportSep 8, 2023Material contractSEC
10-Q · Quarterly reportAug 11, 2023Quarterly reportSEC
8-K · Current reportAug 10, 2023ResultsSEC
8-K · Current reportJul 21, 2023Current reportSEC
8-K · Current reportJul 5, 2023Management or board changeSEC
4 · Change in ownershipJul 5, 2023Insider tradeSEC
4 · Change in ownershipJul 5, 2023Insider tradeSEC
4 · Change in ownershipJul 5, 2023Insider tradeSEC
4 · Change in ownershipJul 5, 2023Insider tradeSEC
4 · Change in ownershipJul 5, 2023Insider tradeSEC
4 · Change in ownershipJul 5, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
424B3 · ProspectusJun 28, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 28, 2023Other filingsSEC
8-K · Current reportJun 26, 2023Meeting outcomeSEC
CORRESP · Letter to the SECJun 23, 2023Other filingsSEC
UPLOAD · Letter from the SECJun 22, 2023Other filingsSEC
S-3 · Registration statementJun 16, 2023Offer documentSEC
8-K · Current reportMay 22, 2023Current reportSEC
10-Q · Quarterly reportMay 12, 2023Quarterly reportSEC
8-K · Current reportMay 12, 2023ResultsSEC
424B3 · ProspectusMay 4, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 4, 2023Other filingsSEC
CORRESP · Letter to the SECMay 1, 2023Other filingsSEC
DEFA14A · Additional proxy materialApr 28, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
8-K · Current reportApr 17, 2023Current reportSEC
UPLOAD · Letter from the SECApr 17, 2023Other filingsSEC
S-1 · Registration statementApr 10, 2023Offer documentSEC
4 · Change in ownershipApr 4, 2023Insider tradeSEC
10-K · Annual reportMar 31, 2023Annual reportSEC
8-K · Current reportMar 30, 2023ResultsSEC
8-K · Current reportMar 8, 2023Management or board changeSEC
8-K · Current reportMar 2, 2023Material contractSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
DFeb 14, 2023Other filingsSEC
S-8 · Registration statement for employee plansFeb 10, 2023Offer documentSEC
8-K · Current reportFeb 10, 2023Current reportSEC
8-K · Current reportFeb 3, 2023Management or board changeSEC
8-K · Current reportFeb 1, 2023Material contractSEC
424B5 · ProspectusJan 31, 2023Offer documentSEC
8-K · Current reportJan 25, 2023Current reportSEC
DEFA14A · Additional proxy materialJan 17, 2023Meeting noticeSEC
SC 13D/A · Big-stake notice, amendedJan 6, 2023Big-stake noticeSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC
DEFA14A · Additional proxy materialJan 4, 2023Meeting noticeSEC
SC 13G · Big-stake noticeJan 4, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedDec 14, 2022Big-stake noticeSEC
DEFA14A · Additional proxy materialNov 18, 2022Meeting noticeSEC
DEF 14A · Proxy statementNov 18, 2022Meeting noticeSEC
10-Q · Quarterly reportNov 10, 2022Quarterly reportSEC
8-K · Current reportNov 10, 2022ResultsSEC
PRE 14A · Preliminary proxy statementNov 8, 2022Meeting noticeSEC
8-K · Current reportNov 8, 2022Acquisition or disposalSEC
8-K · Current reportNov 4, 2022Management or board changeSEC
SC 13D/A · Big-stake notice, amendedOct 19, 2022Big-stake noticeSEC
8-K · Current reportOct 18, 2022Current reportSEC
SC 13G · Big-stake noticeOct 17, 2022Big-stake noticeSEC
SC 13G · Big-stake noticeOct 17, 2022Big-stake noticeSEC
4 · Change in ownershipOct 13, 2022Insider tradeSEC
8-K · Current reportOct 12, 2022Material contractSEC
424B4 · ProspectusOct 11, 2022Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 7, 2022Other filingsSEC
FWP · Free writing prospectusOct 6, 2022Offer documentSEC
S-1/A · Registration statement, amendedOct 6, 2022Offer documentSEC
CORRESP · Letter to the SECOct 5, 2022Other filingsSEC
CORRESP · Letter to the SECOct 5, 2022Other filingsSEC
S-1/A · Registration statement, amendedOct 4, 2022Offer documentSEC
8-K · Current reportSep 30, 2022Current reportSEC
8-K · Current reportSep 22, 2022Current reportSEC
UPLOAD · Letter from the SECSep 2, 2022Other filingsSEC
S-1 · Registration statementAug 31, 2022Offer documentSEC
8-K · Current reportAug 31, 2022Current reportSEC
DEF 14CAug 22, 2022Meeting noticeSEC
10-Q · Quarterly reportAug 15, 2022Quarterly reportSEC
8-K · Current reportAug 12, 2022Current reportSEC
PRE 14CAug 10, 2022Meeting noticeSEC
3 · Initial statement of ownershipAug 3, 2022Insider tradeSEC
8-K · Current reportAug 3, 2022Management or board changeSEC
8-K · Current reportJul 29, 2022Meeting outcomeSEC
SC 13D/A · Big-stake notice, amendedJul 28, 2022Big-stake noticeSEC
3 · Initial statement of ownershipMay 25, 2022Insider tradeSEC
8-K · Current reportMay 25, 2022Current reportSEC
3 · Initial statement of ownershipMay 17, 2022Insider tradeSEC
8-K · Current reportMay 16, 2022Material contractSEC
10-Q · Quarterly reportMay 16, 2022Quarterly reportSEC
8-K · Current reportMay 13, 2022Management or board changeSEC

This page holds 200 of 424 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Avenue Therapeutics, Inc.’s releases · as of Aug 4, 2026

Common shares
3,294,967
Fully diluted
3,294,967

Fully diluted

LineSharesAs of
Common shares3,294,967Aug 4, 2026

Share count over time

CountShares
Aug 4, 20263,294,967

Open Cap table

Shareholders

StakeStakeSharesDateFiling
Fortress Biotech, Inc.13.40%440KJan 2, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Michael S. Weiss
Other companies: Mustang Bio, Inc. (Chairman of the Board of Directors · Since at least Sep 26, 2016); Checkpoint Therapeutics Inc (Director · Since at least Sep 9, 2016); Fortress Biotech, Inc. (Executive Vice Chairman, Strategic Development · Since at least Jan 1, 2016); TG Therapeutics, Inc. (Chairman, President, and Chief Executive Officer · Since at least Dec 31, 2015); National Holdings Corporation (Director · Sep 12, 2016 – Sep 12, 2016 · Past)
Director · Mar 13, 2017 – Aug 7, 2018 · Past
Lindsay A. Rosenwald
Other companies: Mustang Bio, Inc. (Director · Since at least Nov 5, 2026); Checkpoint Therapeutics Inc (Director · Since at least May 14, 2024); Journey Medical Corporation (Director · Since at least Mar 22, 2024); Fortress Biotech, Inc. (PRESIDENT, CEO & CHAIRMAN, Director · Since at least Nov 14, 2023)
Director · Since at least Sep 23, 2024
Neil Herskowitz
Other companies: Journey Medical Corporation (Director · Since at least Nov 16, 2021); Checkpoint Therapeutics Inc (Director · Since at least Jun 14, 2018); Mustang Bio, Inc. (Director · Since at least Jun 14, 2018); National Holdings Corporation (Director · Feb 12, 2018 – Feb 12, 2018 · Past)
Director · Since at least Oct 9, 2017
David Jin
Other companies: Mustang Bio, Inc. (Director · Since at least Nov 5, 2026); Fortress Biotech, Inc. (Chief Financial Officer and Head of Corporate Development · Since at least Apr 1, 2026)
Interim Chief Financial Officer and Chief Operating Officer · Since at least Nov 5, 2026
Curtis Oltmans
Other companies: Fulcrum Therapeutics, Inc. (Chief Legal Officer · Since at least Nov 30, 2020)
Director · Since at least Apr 1, 2021
Elizabeth Garrett Ingram
Other companies: MannKind Corporation (Chief Marketing Officer · Jun 14, 2018 – May 14, 2019 · Past)
Director · Aug 1, 2019 – Sep 12, 2019 · Past
Thomas Gregory Moore
Other companies: Akorn Inc (Director · Jan 24, 2019 – Jan 24, 2019 · Past)
Director · Apr 30, 2019 – Apr 30, 2019 · Past
Akhtar SamadDirector · Mar 13, 2017 – Aug 7, 2018 · Past
Alexandra MacLeanChief Executive Officer, Director · Since at least Feb 23, 2026
Faith CharlesDirector · Since at least Nov 5, 2026
All 14 people
PersonSeat
Jaideep Ashok GogtayDirector · Feb 8, 2019 – Feb 8, 2019 · Past
Jay KranzlerChairman of the Board of Directors · Since at least Nov 5, 2026
Nishant SaxenaDirector · Feb 8, 2019 – Feb 8, 2019 · Past
Scott ReinesInterim Chief Medical Officer · Mar 13, 2017 – Aug 7, 2018 · Past

Open People

Log in to ask 6ix AI your own questions about Avenue Therapeutics, Inc.